Despite the ORR in this study being considerably lower than that reported for brentuximab vedotin in a single-arm phase 2 trial (ORR 75%), the PFS was encouragingly longer with everolimus (8.0 months) than the 5.6 months reported for brentuximab in patients with CD30+ relapsed or refractory HL following high-dose chemotherapy with AHSCT [13]. The gene discussed is TNFRSF8; the disease is Hodgkins lymphoma.